GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Operating Cash Flow
Cash generated by the company's core business operations during the period.
GeneDx Holdings Corp.NASDAQ: WGS
Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Operating cash flow turns negative
Q2 FY2026 operating cash flow was -$28.98M, compared with $10.42M a year earlier. Trailing-twelve-month operating cash flow was -$48.71M.
Context
- Operating cash flow amounted to 7.8% of revenue in FY2025, down 1.5 pp from a year earlier.
- Operating cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly operating cash flow holds near -$28.98M or moves back toward the trailing-twelve-month quarterly average of -$12.18M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 33.28M USD
- Year-over-year change
- +216.8%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 33.28M | +216.8% |
| FY2024 | 2024-12-31 | (28.5M) | +84.2% |
| FY2023 | 2023-12-31 | (180.15M) | +43.6% |
| FY2022 | 2022-12-31 | (319.16M) | -67.6% |
| FY2021 | 2021-12-31 | (190.43M) | — |
Operating Cash Flow vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's LTM Jun 2026 operating cash flow of $48.71M is the 3rd largest of the 9 companies compared; the peer median is $4.01M.
- Its year-over-year change of -474.0% is the 7th highest of 8, against a peer median of +5.4%.
- Operating cash flow amounts to 10.7% of revenue for WGS, versus a peer median of 12.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $90.11M | -1062.4% | — | 28.1% | |
| LTM Mar 2026 | $79.46M | +86.1% | +2.2% | 123.2% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $48.71M | -474.0% | — | 10.7% |
| LTM Mar 2026 | $48.25M | -26.5% | — | 14.2% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $45.35M | — | — | 11.4% |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $23.97M | +5.4% | -21.3% | 1229.6% |
| LTM Jun 2026 | $22.05M | +56.9% | — | 2.9% | |
| FY2025 | $10.42M | -43.8% | -32.7% | 9.7% | |
| LTM Mar 2026 | $2.4M | +137.5% | — | 0.3% | |
| Peer median (excluding WGS) | $4.01M | +5.4% | -21.3% | 12.8% | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (245.39M) | (548.98M) | (175.77M) | (52.29M) | (21.02M) |
| Depreciation & Amortization | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M |
| Deferred Income Tax | 0 | (49.12M) | (926K) | (343K) | 0 |
| Stock-Based Compensation | 219.42M | 41.98M | (326K) | 9.14M | 32.16M |
| Change in Working Capital | 8.08M | 36.13M | (38.24M) | (24.75M) | (15.6M) |
| Accounts Receivables | 5.54M | 5.53M | 10.26M | (5.42M) | (36.23M) |
| Inventory | (10.62M) | 4.6M | 975K | (2.59M) | (3.44M) |
| Accounts Payables | 0 | 34.46M | (46.95M) | (20.46M) | 12.1M |
| Other Working Capital | 13.17M | (8.46M) | (2.53M) | 3.72M | 11.97M |
| Other Non-Cash Items | (194.35M) | 141.53M | 1.38M | 17.79M | 12.51M |
| Operating Cash Flow | (190.43M) | (319.16M) | (180.15M) | (28.5M) | 33.28M |
| Capital Expenditures | (20.79M) | (14.32M) | (5.71M) | (5.49M) | (19.02M) |
| Acquisitions (Net) | 0 | (127M) | (8.11M) | 0 | (32.86M) |
| Purchases of Investments | 0 | 0 | (47.67M) | (66.3M) | (55.68M) |
| Sales of Investments | 0 | 0 | 17.77M | 41.66M | 46.03M |
| Other Investing Activities | (11.39M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (20.79M) | (141.33M) | (43.73M) | (30.13M) | (61.52M) |
| Debt Repayment | (13.47M) | (3.29M) | 42.95M | (3.23M) | (3.66M) |
| Common Stock Issued | 442.68M | 197.66M | 143M | 46.5M | 51.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 64.51M | 2.95M | 285K | 891K | 0 |
| Financing Cash Flow | 493.73M | 197.32M | 186.24M | 44.16M | 48.03M |
| Effect of Forex Changes | 0 | 0 | (87K) | 0 | 0 |
| Net Change in Cash | 282.51M | (263.17M) | (37.72M) | (14.47M) | 19.79M |
| Free Cash Flow | (211.22M) | (333.48M) | (185.86M) | (33.99M) | 14.26M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.